Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown cardioprotective effects in patients with diabetes, suggesting potential benefits in reducing AF incidence.<h4>Methods</h4>We retrospectively analyzed clinical data from patients with T2DM diagnosed with DCM treated at the First Affiliated Hospital of Xi'an Jiaotong University between January 2018 and January 2024. The gene discussed is SLC5A2; the disease is diabetes mellitus.